Skip to content

Study of Unani formulation in headache

Effect of Habb-e-Quqaya in Shaqeeqa (Migraine without Aura)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/01/011591
Enrollment
30
Registered
2018-01-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Migraine

Interventions

Intervention1: Habb-e-Quqaya: 3 gram orally daily in two divided doses Control Intervention1: Not Applicable: Not Applicable

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients clinically diagnosed according to ICHD criteria Patients between 18-60 years of age Patients of either gender Willing to complete daily dairy Willing to take medication for 45 days

Exclusion criteria

Exclusion criteria: Patients below 18 and above 60 years of age Pregnancy and lactation Major Systemic disorders Patients with known psychiatric and mental disorders

Design outcomes

Primary

MeasureTime frame
reduction in Headache frequency (From the daily headache diary) Reduction in MIDAS (Migraine disability assessment) score Reduction in Headache intensity by VAS (Visual analogue scale) Timepoint: before treatment, 15th day, 30th day, 45th day

Secondary

MeasureTime frame
Reduction in Headache (Unilateral or Bilateral) &/ (Pulsating or non pulsating quality) Nausea vomiting Photophobia Phonophobia Timepoint: Before treatment, 15th day, 30th day, 45th day

Countries

India

Contacts

Public ContactDr Muzaffar Din Ahmad Bhat

National Institute of Unani Medicine

drmuzaffar79@gmail.com8618643497

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026